Effects of adrenergic stimulation on ventilation in man.
The mechanism by which catecholamines affect ventilation in man is not known. Ventilatory responses to catecholamines were observed in normal subjects before and after adrenergic receptor blockade. Intravenous infusions of norepinephrine and isoproterenol caused significant increases in minute volume and decreases in end-tidal P(Co2) which were blocked by the administration of propranolol, a beta adrenergic receptor blocker. The hyperventilatory response to hypoxia was not altered by propranolol. Intravenous infusion of phenylephrine caused a small but significant decrease in minute volume which was antagonized by phentolamine, an alpha adrenergic receptor blocker. Angiotensin, a nonadrenergic pressor agent, also decreased minute volume significantly.100% oxygen was administered to suppress arterial chemoreceptors. Increases in minute volume and decreases in arterial P(Co2) in response to norepinephrine and isoproterenol were blocked by breathing 100% oxygen. The decrease in minute volume during phenylephrine was not altered by 100% oxygen. THE RESULTS INDICATE THAT: (a) beta adrenergic receptors mediate the hyperventilatory response to norepinephrine and isoproterenol but not to hypoxia. (b) the pressor agents phenylephrine and angiotensin decrease ventilation, and (c) suppression of chemoreceptors blocks the ventilatory response to norepinephrine and isoproterenol but not to phenylephrine. Implications concerning the interaction of adrenergic receptors and chemoreceptors with respect to the hyperventilatory response to catecholamines are discussed.
D000328:Adult; D000704:Analysis of Variance; D000804:Angiotensin II / Q000494:pharmacology; D002245:Carbon Dioxide / Q000097:blood; D002628:Chemoreceptor Cells / Q000187:drug effects / Q000502:physiology*; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004336:Drug Antagonism; D005260:Female; D006801:Humans; D006985:Hyperventilation / Q000139:chemically induced; D000860:Hypoxia / Q000503:physiopathology; D007545:Isoproterenol / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010656:Phenylephrine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D012119:Respiration / Q000187:drug effects*; D013147:Spirometry; D013268:Stimulation, Chemical
D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D000804:Angiotensin II; D002245:Carbon Dioxide; D010656:Phenylephrine; D011433:Propranolol; D007545:Isoproterenol; D009638:Norepinephrine